Plain-English translation of NCT03947385 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called to see if it works against solid tumors that have specific genetic changes (GNAQ/11 mutations or PRKC fusions). Researchers want to find the right dose of this medication and understand how well it controls tumors, either on its own or combined with other existing cancer drugs.
Many solid tumors have genetic changes that make them hard to treat with standard therapies, and patients need new treatment options. This study is exploring whether targeting these specific genetic changes with this medication could help control cancer growth better.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily in 28-day cycles. The study includes two phases: first, researchers find the safest and most effective dose, then in the second phase, more patients receive that dose to see how well the treatment works. You'll have regular visits to the clinic for blood tests, scans, and check-ins with your doctor to monitor how you're responding and any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States